American Research Corporation at the Texas Liver Institute | San Antonio, TX

Research site

(Unclaimed)

Location

607 Camden Street, San Antonio, Texas, United States of America

Site insights

Top conditions

Top treatments

EDP-305

BI 685509

Elafibranor

Obeticholic Acid

Ursodeoxycholic Acid

Cilofexor

Firsocostat

ALN-HSD

EYE103

HM15211

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 40 total trials

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis (ELFIDENCE)

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver).PBC is a slowly progressiv...

Enrolling

Primary Biliary Cholangitis (PBC)

Drug: Elafibranor

Other: Matched 80 mg placebo

Status recently updated

A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

Part A is a randomized, double-blind, placebo-controlled, multi-center Proof-of-Concept (POC) Trial in subjects with severe Alopecia Areata. All part...

Active, not recruiting

Enrolling

Alopecia Areata

Drug: bempikibart (ADX-914)

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition (NASHGEN-2)

This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have metabolic...

Enrolling

Metabolic Dysfunction-associated Steatohepatitis (MASH)

Drug: Placebo

Drug: ALN-HSD

A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE)

The participants in this study will have confirmed PBC with inadequate response or intolerance to Ursodeoxycholic acid (UDCA), which is a medication...

Enrolling

Primary Biliary Cholangitis

Other: Placebo

Drug: Elafibranor

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. (ELMWOOD)

This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease...

Active, not recruiting

Primary Sclerosing Cholangitis

Drug: Placebo Matched to Elafibranor 80 mg

Drug: Placebo Matched to Elafibranor 120 mg

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME (BRUNELLO)

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active...

Enrolling

Diabetic Macular Edema (DME)

Drug: EYE103

Drug: Ranibizumab

A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH

This study is open to people with cirrhosis caused by a liver disease called MASH (metabolic dysfunction-associated steatohepatitis). The purpose of...

Enrolling

Metabolic Dysfunction Associated Steatohepatitis (MASH)

Compensated Liver Cirrhosis

Drug: BI 770371

Drug: Placebo for BI 770371

A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems

This study is open to adults between 18 and 80 years of age. People with a body mass index (BMI) between 18 and 42 kg/m\^2 can take part. Women can o...

Enrolling

Healthy

Liver Diseases

Drug: Zongertinib (BI 1810631)

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Active, not recruiting

Primary Biliary Cirrhosis

Drug: Seladelpar 10 mg Capsule

Drug: Seladelpar 5 mg Capsule

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (...

Active, not recruiting

Primary Biliary Cholangitis

Drug: Obeticholic Acid placebo

Drug: Obeticholic Acid 5 mg